Celltrion acquires Asia-Pacific business of 18 Takeda Pharma brands
- 4 years ago
셀트리온, 종합제약사 도약•••다케다 아•태 사업 인수
South Korean biopharmaceutical company Celltrion will acquire the business rights for a total of 18 brands belonging to Japan's Takeda Pharmaceutical ... the first major deal for the Korean firm in upgrading its global presence.
Under the 278 million U.S. dollar deal, Celltrion will secure the patents, trademarks and sales rights of the products in nine Asia-Pacific markets, including South Korea, Australia and Singapore.
The 18 brands raked in combined sales of 140 million dollars in the region in 2018 alone.
Celltrion said it will be on the market through its affiliates Celltrion Pharma and Celltrion Healthcare.
The company had a market value of 247 million dollars last year,.. up over 17-and-a-half percent on-year.
South Korean biopharmaceutical company Celltrion will acquire the business rights for a total of 18 brands belonging to Japan's Takeda Pharmaceutical ... the first major deal for the Korean firm in upgrading its global presence.
Under the 278 million U.S. dollar deal, Celltrion will secure the patents, trademarks and sales rights of the products in nine Asia-Pacific markets, including South Korea, Australia and Singapore.
The 18 brands raked in combined sales of 140 million dollars in the region in 2018 alone.
Celltrion said it will be on the market through its affiliates Celltrion Pharma and Celltrion Healthcare.
The company had a market value of 247 million dollars last year,.. up over 17-and-a-half percent on-year.